670 related articles for article (PubMed ID: 33149733)
1. The Inflammasome in Times of COVID-19.
de Rivero Vaccari JC; Dietrich WD; Keane RW; de Rivero Vaccari JP
Front Immunol; 2020; 11():583373. PubMed ID: 33149733
[TBL] [Abstract][Full Text] [Related]
2. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
3. A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients.
Roncati L; Ligabue G; Nasillo V; Lusenti B; Gennari W; Fabbiani L; Malagoli C; Gallo G; Giovanella S; Lupi M; Salviato T; Paolini A; Costantini M; Trenti T; Maiorana A
Platelets; 2020 Nov; 31(8):1085-1089. PubMed ID: 32857624
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.
Costela-Ruiz VJ; Illescas-Montes R; Puerta-Puerta JM; Ruiz C; Melguizo-Rodríguez L
Cytokine Growth Factor Rev; 2020 Aug; 54():62-75. PubMed ID: 32513566
[TBL] [Abstract][Full Text] [Related]
5. Cytokine Storms: Understanding COVID-19.
Mangalmurti N; Hunter CA
Immunity; 2020 Jul; 53(1):19-25. PubMed ID: 32610079
[TBL] [Abstract][Full Text] [Related]
6. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.
Conti P; Ronconi G; Caraffa A; Gallenga CE; Ross R; Frydas I; Kritas SK
J Biol Regul Homeost Agents; 2020 March-April,; 34(2):327-331. PubMed ID: 32171193
[TBL] [Abstract][Full Text] [Related]
7. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation.
Li S; Zhang Y; Guan Z; Li H; Ye M; Chen X; Shen J; Zhou Y; Shi ZL; Zhou P; Peng K
Signal Transduct Target Ther; 2020 Oct; 5(1):235. PubMed ID: 33037188
[TBL] [Abstract][Full Text] [Related]
9. [Progress on role of cytokine storm in exacerbation of coronavirus disease 2019 (COVID-19): Review].
Liao J; Wen B; Deng X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Oct; 36(10):941-947. PubMed ID: 33148390
[TBL] [Abstract][Full Text] [Related]
10. Inflammation, Thrombosis, and Destruction: The Three-Headed Cerberus of Trauma- and SARS-CoV-2-Induced ARDS.
Lupu L; Palmer A; Huber-Lang M
Front Immunol; 2020; 11():584514. PubMed ID: 33101314
[TBL] [Abstract][Full Text] [Related]
11. Severe COVID-19: NLRP3 Inflammasome Dysregulated.
van den Berg DF; Te Velde AA
Front Immunol; 2020; 11():1580. PubMed ID: 32670297
[TBL] [Abstract][Full Text] [Related]
12. The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections.
Zhang YY; Li BR; Ning BT
Front Immunol; 2020; 11():2033. PubMed ID: 32922406
[TBL] [Abstract][Full Text] [Related]
13. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.
Coperchini F; Chiovato L; Croce L; Magri F; Rotondi M
Cytokine Growth Factor Rev; 2020 Jun; 53():25-32. PubMed ID: 32446778
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684
[TBL] [Abstract][Full Text] [Related]
15. Targeting the NLRP3 Inflammasome in Severe COVID-19.
Freeman TL; Swartz TH
Front Immunol; 2020; 11():1518. PubMed ID: 32655582
[TBL] [Abstract][Full Text] [Related]
16. Inflammasome formation in the lungs of patients with fatal COVID-19.
Toldo S; Bussani R; Nuzzi V; Bonaventura A; Mauro AG; Cannatà A; Pillappa R; Sinagra G; Nana-Sinkam P; Sime P; Abbate A
Inflamm Res; 2021 Jan; 70(1):7-10. PubMed ID: 33079210
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD).
Gagiannis D; Steinestel J; Hackenbroch C; Schreiner B; Hannemann M; Bloch W; Umathum VG; Gebauer N; Rother C; Stahl M; Witte HM; Steinestel K
Front Immunol; 2020; 11():587517. PubMed ID: 33123171
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
19. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
[TBL] [Abstract][Full Text] [Related]
20. Cytokine release syndrome in severe COVID-19.
Moore JB; June CH
Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
[No Abstract] [Full Text] [Related]
[Next] [New Search]
